-
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Wednesday, August 14, 2024 - 2:34pm | 702Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...
-
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
Tuesday, January 9, 2024 - 4:36pm | 482Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers. Both compounds are novel deuterated DMT...
-
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Monday, October 23, 2023 - 1:39pm | 727Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Following their arrangement plan under the BC Business Corporations Act, and pursuant to the agreement’s terms, Small Pharma is now a wholly-owned subsidiary...
-
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Tuesday, October 3, 2023 - 3:23pm | 404Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants. A DMT formulation, VLS-01 works as a partial agonist of the 5-HT 1A/2A/2C receptors, with an...
-
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
Tuesday, September 26, 2023 - 3:40pm | 466Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) and psychedelic therapy education organization Fluence have signed an agreement to support the streamlining and scaling of the former’s EMBARK facilitator training program in light of an upcoming global Phase 3 trial of deuterated...
-
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
Tuesday, September 26, 2023 - 2:31pm | 638New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. They correspond to U.K.’s short-acting psychedelic therapies developer Small Pharma’s (...
-
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Monday, August 28, 2023 - 1:38pm | 678Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and outstanding securities. The deal has already been unanimously approved by both...
-
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
Tuesday, August 1, 2023 - 1:00pm | 495Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for aggregate gross proceeds of $8,250,000. Each unit will equate one common share and one common share...
-
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Monday, June 5, 2023 - 1:56pm | 475Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and...
-
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
Wednesday, May 24, 2023 - 3:47pm | 535Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers....
-
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Thursday, May 11, 2023 - 2:11pm | 441Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials: Cash, cash equivalents and short-term investments of a total $249.9...
-
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Thursday, December 22, 2022 - 4:49pm | 533Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) announced that the last patient has completed its final visit in its Phase IIa clinical study of its proprietary intravenous (IV) DMT formulation SPL026 paired with supportive therapy for the treatment of Major Depressive...
-
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Wednesday, November 16, 2022 - 1:47pm | 378Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands. CEO Christopher J. Moreau said the company is thrilled to initiate...
-
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Friday, November 4, 2022 - 6:08pm | 536Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD). Through its R&D acceleration platform,...
-
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Monday, October 24, 2022 - 12:27pm | 403Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has signed an investigator-initiated clinical trial agreement with Yale University -a recurring type of alliance within the psychedelics space- for the study of multiple intravenous (IV) doses of DMT for the...